{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:35:21Z","timestamp":1793907321768,"version":"4.8.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.annonc.2021.12.003","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T05:35:42Z","timestamp":1639632942000},"page":"259-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":447,"title":["Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)"],"prefix":"10.1016","volume":"33","author":[{"given":"P.J.","family":"Hayden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roddie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.W.","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sanchez-Guijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"K\u00f6hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kuball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Styczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Topp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.U.","family":"Ispizua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Vrhovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.12.003_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/CCO.0000000000000667","article-title":"Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"32","author":"Beauvais","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.annonc.2021.12.003_bib5","first-page":"93","article-title":"Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives","volume":"65","author":"Gauthier","year":"2017","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib6","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A\u00a0phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.annonc.2021.12.003_bib8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19(+) relapsed\/refractory malignancies","volume":"29","author":"Ortiz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.annonc.2021.12.003_bib9","first-page":"50","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.annonc.2021.12.003_bib11","first-page":"79","article-title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT","volume":"67","author":"Hayden","year":"2019","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib12","first-page":"59","article-title":"Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations","volume":"66","author":"Chabannon","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib13","first-page":"57","article-title":"Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"66","author":"Yakoub-Agha","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jca.21812","article-title":"Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric\/adolescent acute lymphoblastic leukemia patients","volume":"35","author":"Jarisch","year":"2020","journal-title":"J\u00a0Clin Apher"},{"issue":"5","key":"10.1016\/j.annonc.2021.12.003_bib15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/cells9051225","article-title":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed\/refractory NHL or ALL","volume":"9","author":"Korell","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.annonc.2021.12.003_bib16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.annonc.2021.12.003_bib17","doi-asserted-by":"crossref","first-page":"102769","DOI":"10.1016\/j.transci.2020.102769","article-title":"Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients","volume":"59","author":"Hutt","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.annonc.2021.12.003_bib18","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.annonc.2021.12.003_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/vox.12164","article-title":"A\u00a0safe therapeutic apheresis protocol in paediatric patients weighing 11 to 25 kg","volume":"107","author":"Maitta","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.annonc.2021.12.003_bib20","first-page":"85","article-title":"Large volume leukapheresis is efficient and safe even in small children up to 15 kg body weight","volume":"15","author":"Bojanic","year":"2017","journal-title":"Blood Transfus"},{"key":"10.1016\/j.annonc.2021.12.003_bib21","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib24","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2021.12.003_bib25","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib26","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib27","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.12.003_bib28","series-title":"Regulation (EC) N\u00b0 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and amending Directive 2001\/83\/EC and Regulation (EC) n\u00b0726\/2004 (text with EEA relevance)","year":"2007"},{"key":"10.1016\/j.annonc.2021.12.003_bib29","volume":"2021","year":"2007"},{"key":"10.1016\/j.annonc.2021.12.003_bib30","year":"2009"},{"key":"10.1016\/j.annonc.2021.12.003_bib31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jcyt.2019.07.004","article-title":"Preservation of cell-based immunotherapies for clinical trials","volume":"21","author":"Li","year":"2019","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.annonc.2021.12.003_bib32","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.annonc.2021.12.003_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annonc.2021.12.003_bib34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2021.12.003_bib35","doi-asserted-by":"crossref","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.annonc.2021.12.003_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jmii.2021.02.006","article-title":"Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy","volume":"54","author":"Beauvais","year":"2021","journal-title":"J\u00a0Microbiol Immunol Infect"},{"issue":"2","key":"10.1016\/j.annonc.2021.12.003_bib37","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2021.12.003_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-019-0309-6","article-title":"Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome","volume":"17","author":"Halyabar","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.annonc.2021.12.003_bib39","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.annonc.2021.12.003_bib40","first-page":"103285","article-title":"The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity","volume":"69","author":"Aqel","year":"2021","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib41","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.annonc.2021.12.003_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2021.12.003_bib43","first-page":"159","article-title":"Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials","volume":"68","author":"Yassine","year":"2020","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib44","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.12.003_bib45","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2021.12.003_bib46","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.annonc.2021.12.003_bib47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annonc.2021.12.003_bib48","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib49","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or\u00a0relapsed non-Hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2021.12.003_bib50","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA adverse events reporting system analysis","volume":"26","author":"Guha","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annonc.2021.12.003_bib51","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2021.12.003_bib52","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annonc.2021.12.003_bib53","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.annonc.2021.12.003_bib54","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","article-title":"Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?","volume":"8","author":"Gudiol","year":"2021","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.annonc.2021.12.003_bib55","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib56","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib57","doi-asserted-by":"crossref","first-page":"e28092","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2021.12.003_bib58","first-page":"e146743","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.annonc.2021.12.003_bib59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/bjh.17737","article-title":"Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation","volume":"195","author":"Gabelli","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2021.12.003_bib60","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.annonc.2021.12.003_bib61","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.annonc.2021.12.003_bib62","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.annonc.2021.12.003_bib63","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annonc.2021.12.003_bib64","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annonc.2021.12.003_bib65","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","article-title":"G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma","volume":"55","author":"Galli","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.annonc.2021.12.003_bib66","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annonc.2021.12.003_bib67","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1097\/HS9.0000000000000545","article-title":"Hematologic rescue of CAR T-cell-mediated prolonged pancytopenia using autologous peripheral blood hematopoietic stem cells in a lymphoma patient","volume":"5","author":"Godel","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.annonc.2021.12.003_bib68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.15012","article-title":"CD34(+) selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation","volume":"180","author":"Mainardi","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2021.12.003_bib69","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib70","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells","volume":"139","author":"Bishop","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib71","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.annonc.2021.12.003_bib72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib73","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/bloodadvances.2021004176","article-title":"Effective anti-BCMA retreatment in multiple myeloma","volume":"5","author":"Gazeau","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.annonc.2021.12.003_bib74","first-page":"111","article-title":"CAR T-cell treatment during the COVID-19 pandemic: management strategies and challenges","volume":"68","author":"Hu","year":"2020","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib75","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.12.003_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001114","article-title":"Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2","volume":"8","author":"Wang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2021.12.003_bib77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib78","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.003_bib79","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41409-020-01099-4","article-title":"Axicabtagene ciloleucel CAR T-cell therapy for relapsed\/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?","volume":"56","author":"Ghafouri","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.annonc.2021.12.003_bib80","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib81","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annonc.2021.12.003_bib82","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/CCM.0b013e3182a66b76","article-title":"Cornell assessment of pediatric delirium: a valid, rapid, observational tool for screening delirium in the PICU\u2217","volume":"42","author":"Traube","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.annonc.2021.12.003_bib83","article-title":"SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: A systematic review and preliminary observations","author":"Abid","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.annonc.2021.12.003_bib84","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.annonc.2021.12.003_bib85","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbmt.2011.12.519","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"18","author":"Majhail","year":"2012","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421048766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421048766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:07:28Z","timestamp":1760335648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421048766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0923753421048766"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.12.003","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}